[1]张春芳,徐双兰,赵方允,等.表观遗传学在肺动脉高压发病机制和治疗中的研究进展[J].中国药理学通报,2018,(08):1041-1044.[doi:10.3969/j.issn.1001-1978.2018.08.002]
 ZHANG Chun-fang,XU Shuang-lan,ZHAO Fang-yun,et al.Research progress of epigenetic in pathophysiology and therapeutics of pulmonary hypertension[J].Chinese Pharmacological Bulletin,2018,(08):1041-1044.[doi:10.3969/j.issn.1001-1978.2018.08.002]
点击复制

表观遗传学在肺动脉高压发病机制和治疗中的研究进展()
分享到:

《中国药理学通报》[ISSN:/CN:]

卷:
期数:
2018年08期
页码:
1041-1044
栏目:
讲座与综述
出版日期:
2018-07-26

文章信息/Info

Title:
Research progress of epigenetic in pathophysiology and therapeutics of pulmonary hypertension
文章编号:
1001-1978(2018)08-1041-04
作者:
张春芳1徐双兰1赵方允2邢西迁1杨 姣3
昆明医科大学附属延安医院 1.呼吸内一科、2.药学部,云南 昆明 650051; 3.昆明医科大学第一附属医院呼吸内一科,云南 昆明 650032
Author(s):
ZHANG Chun-fang1 XU Shuang-lan1 ZHAO Fang-yun2 XING Xi-qian1 YANG Jiao3
1.the First Dept of Respiratory Medicine, 2.College of Pharmacy, Yan'an Hospital Affiliated to Kunming Medical University, Kunming 650051, China; 3.the First Dept of Respiratory Medicine, the First Affiliated Hospital of Kunming Medical University, Kunming 650032, China
关键词:
表观遗传学 DNA甲基化 DNA甲基转移酶 组蛋白修饰 组蛋白乙酰化 肺动脉高压
Keywords:
epigenetics DNA methylation DNA methyltransferase histone modification histone acetylation pulmonary hypertension
分类号:
R-05; R394; R544.022; R544.05; R977.3; R977.6
DOI:
10.3969/j.issn.1001-1978.2018.08.002
文献标志码:
A
摘要:
表观遗传学是研究在DNA序列没有改变的情况下,基因功能可逆的、可遗传改变的一门生物学学科。表观遗传学与众多复杂性疾病的发生、发展密切相关,同样与肺动脉高压的发生、发展相关。该文主要对部分表观遗传成分和基因DNA甲基化和组蛋白修饰在肺动脉高压发生、发展中的作用,DNA甲基化转移酶抑制剂、组蛋白去乙酰化酶抑制剂及其他潜在治疗靶点对肺动脉高压的治疗作用及机制进行了综述。
Abstract:
Epigenetics, as the latest biological science in recent years, refers to the changes and reversible gene function in phenotype and gene expression without alterations in DNA sequence.Epigenetics is associated with the occurrence and development of sorts of complex disorders, which can be applied to pulmonary hypertension.In this review, we summarize the basics of two types of epigenetic modification mediated by DNA methylation, the post-translational modifications of histone tails and the known sites and molecules involved in pulmonary hypertension, as well as the inhibitor of histone deacetylas, inhibitor of DNA methyltransferase and the underlying therapy mechanisms.

参考文献/References:

[1] Kim G H, Ryan J J, Marsboom G, et al.Epigenetic mechanisms of pulmonary hypertension [J].Pulm Circ, 2011, 1(3): 347-56.
[2] Sharma S, Kelly T K, Jones P A.Epigenetics in cancer [J].Carcinogenesis, 2010, 31(1): 27-36.
[3] 宫荟萃, 王运良, 王红卫.阿尔茨海默病的表观遗传学机制及相关药物研究 [J].药学学报, 2013, 48(7): 1005-13.
[3] Gong H C, Wang Y L, Wang H W.Epigenetic mechanisms of Alzheimer's disease and related drug research [J].Acta Pharm Sin, 2013, 48(7): 1005-13.
[4] Lorenzen J M, Martino F, Thum T.Epigenetic modifications in cardiovascular disease [J].Basic Res Cardiol, 2012, 107(2): 245.
[5] Chelladurai P, Seeger W, Pullamsetti S S.Epigenetic mechanisms in pulmonary arterial hypertension: the need for global perspectives [J].Eur Respir Rev, 2016, 25(140): 135-40.
[6] Latham K E, Sapienza C,Engel N.The epigenetic lorax: gene-environment interactions in human health [J].Epigenomics, 2012, 4(4): 383-402.
[7] Hashimoto H, Vertino P M,Cheng X.Molecular coupling of DNA methylation and histone methylation [J].Epigenomics, 2010, 2(5): 657-69.
[8] Archer S L.Acquired mitochondrial abnormalities, including epigenetic inhibition of superoxide dismutase 2, in pulmonary hypertension and cancer: therapeutic implications [J].Adv Exp Med Biol, 2016, 903:29-53.
[9] Chen F, Li X, Aquadro E, et al.Inhibition of histone deacetylase reduces transcription of NADPH oxidases and ROS production and ameliorates pulmonary arterial hypertension [J].Free Radic Biol Med, 2016, 99:167-78.
[10] Archer S L, Marsboom G, Kim G H, et al.Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target [J].Circulation, 2010,121(24): 2661-71.
[11] Gamen E, Seeger W,Pullamsetti S S.The emerging role of epigenetics in pulmonary hypertension [J].Eur Respir J, 2016, 48(3): 903-17.
[12] Perros F, Cohen-Kaminsky S, Gambaryan N, et al.Cytotoxic cells and granulysin in pulmonary arterial hypertension and pulmonary veno-occlusive disease [J].Am J Respir Crit Care Med, 2013, 187(2): 189-96.
[13] Madonna R, De Caterina R,Geng Y J.Epigenetic regulation of insulin-like growth factor signaling: a novel insight into the pathophysiology of neonatal pulmonary hypertension [J].Vascul Pharmacol, 2015, 73: 4-7.
[14] Hautefort A, Chesne J, Preussner J, et al.Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension [J].Oncotarget, 2017, 8(32): 52995-3016.
[15] Mathew B, Lakshminrusimha S.Persistent pulmonary hypertension in the newborn [J].Children(Basel), 2017, 4(8): 63.
[16] Subramanian S V, Nadal-Ginard B.Early expression of the different isoforms of the myocyte enhancer factor-2(MEF2)protein in myogenic as well as non-myogenic cell lineages during mouse embryogenesis [J].Mech Dev, 1996, 57(1): 103-12.
[17] Xu Z, Gong J, Maiti D, et al.MEF2C ablation in endothelial cells reduces retinal vessel loss and suppresses pathologic retinal neovascularization in oxygen-induced retinopathy [J].Am J Pathol, 2012, 180(6): 2548-60.
[18] 邓 鋆, 喻珊珊, 张 旭, 等.HIF-1α和HIF-2α在低氧性肺动脉高压中的不同作用研究进展 [J].中国药理学通报, 2017, 33(1): 10-3.
[18] Deng J, Yu S S, Zhang X, et al.Advances in differential roles of HIF-1α and HIF-2α in the pathogenesis of hypoxic pulmonary hypertension [J].Chin Pharmacol Bull, 2017, 33(1):10-3.
[19] Xu X F, Lv Y, Gu W Z, et al.Epigenetics of hypoxic pulmonary arterial hypertension following intrauterine growth retardation rat: epigenetics in PAH following IUGR [J].Respir Res, 2013, 14(1): 20.
[20] 盖祥云, 林鹏程, 何彦峰, 等.低氧性肺动脉高压中低氧性肺血管收缩的作用 [J].中国药理学通报, 2016, 32(6): 768-72.
[20] Gai X Y, Lin P C, He Y F, et al.Effect of hypoxic pulmonary vasoconstriction on hypoxic pulmonary hypertension [J].Chin Pharmacol Bull, 2016, 32(6): 768-72.
[21] Nozik-Grayck E, Woods C, Stearman R S, et al.Histone deacetylation contributes to low extracellular superoxide dismutase expression in human idiopathic pulmonary arterial hypertension [J].Am J Physiol Lung Cell Mol Physiol, 2016, 311(1): L124-34.
[22] De Raaf M A, Hussaini A A, Gomez-Arroyo J, et al.Histone deacetylase inhibition with trichostatin A does not reverse severe angioproliferative pulmonary hypertension in rats(2013 Grover Conference series)[J].Pulm Circ, 2014, 4(2): 237-43.
[23] Zhao L, Chen C N, Hajji N, et al.Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid [J].Circulation, 2012, 126(4): 455-67.
[24] Bogaard H J, Mizuno S, Hussaini A A, et al.Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats [J].Am J Respir Crit Care Med, 2011, 183(10): 1402-10.
[25] Chen D, Gao W, Wang S, et al.Critical effects of epigenetic regulation in pulmonary arterial hypertension [J].Cell Mol Life Sci, 2017, 74(20): 3789-808.

相似文献/References:

[1]林华型,盛树力.阿尔采末病发病机制与表观遗传学研究进展[J].中国药理学通报,2010,(05):570.
 LAM Wah ying,SHENG Shu li.Alzheimer′s disease pathogenesis and apparent progress in genetic research[J].Chinese Pharmacological Bulletin,2010,(08):570.
[2]张玲,盛树力,秦川.表观遗传学药物的研究进展[J].中国药理学通报,2013,(03):297.
 ZHANG Ling,SHENG Shu li,QIN Chuan.Research progress in the epigenetic drug[J].Chinese Pharmacological Bulletin,2013,(08):297.
[3]段菊,凌霜,甘我挺,等.DNA主动去甲基化酶研究进展及药物开发[J].中国药理学通报,2013,(10):1345.
 DUAN Ju,LING Shuang,GAN Wo ting,et al.DNA demethylases: a new direction for drug development[J].Chinese Pharmacological Bulletin,2013,(08):1345.
[4]陈姣,楚世峰,陈乃宏.糖皮质激素与抑郁发病相关机制研究进展[J].中国药理学通报,2013,(11):1493.
 CHEN Jiao,CHU Shi feng,CHEN Nai hong.Research progress in glucocorticoid and pathophysiology of depression[J].Chinese Pharmacological Bulletin,2013,(08):1493.
[5]黄小红,马旭东,黄轶群,等.BIX-01294对Molt-4细胞增殖、凋亡及组蛋白甲基化的影响[J].中国药理学通报,2014,(10):1392.
 HUANG Xiao-hong,MA Xu-dong,HUANG Yi-qun,et al.Effect of BIX-01294 on cell proliferation, apoptosis and histone methylation in Molt-4 line[J].Chinese Pharmacological Bulletin,2014,(08):1392.
[6]赵 丽,曹成建,刘现梅,等.ERO1α及其DNA甲基化在同型半胱氨酸抑制肝细胞增殖中的作用[J].中国药理学通报,2014,(12):1743.
 ZHAO Li,CAO Cheng-jian,LIU Xian-mei,et al.Role of ERO1α and its DNA methylation in homocysteine-induced inhibition of hepatocyte proliferation[J].Chinese Pharmacological Bulletin,2014,(08):1743.
[7]张均田.认知过程中的表观遗传学机制[J].中国药理学通报,2015,(01):1.[doi:10.3969/j.issn.1001-1978.2015.01.001]
 ZHANG Jun-tian.Epigenetic mechanism in cognitive function[J].Chinese Pharmacological Bulletin,2015,(08):1.[doi:10.3969/j.issn.1001-1978.2015.01.001]
[8]李昀,张军航,安军,等.PLCE1调控p53诱导食管癌细胞凋亡的实验研究[J].中国药理学通报,2015,(01):82.[doi:10.3969/j.issn.1001-1978.2015.01.018]
 LI Yun,ZHANG Jun-hang,AN Jun,et al.PLCE1 modulates p53 expression and apoptosis in esophageal cancer cells[J].Chinese Pharmacological Bulletin,2015,(08):82.[doi:10.3969/j.issn.1001-1978.2015.01.018]
[9]刘现梅,曹成建,田 珏,等.miR-125b甲基化在同型半胱氨酸促进血管平滑肌细胞增殖中的作用[J].中国药理学通报,2015,(07):1023.[doi:10.3969/j.issn.1001-1978.2015.07.027]
 LIU Xian-mei,CAO Cheng-jian,TIAN Jue,et al.Role of homocysteine to promote the vascular smooth muscle cell proliferation by MiR-125b methylation[J].Chinese Pharmacological Bulletin,2015,(08):1023.[doi:10.3969/j.issn.1001-1978.2015.07.027]
[10]郭 敏,张宪武,马天宇,等.Aβ25-35对SH-SY5Y细胞Bcl-2、Bax基因启动子区DNA甲基化的影响[J].中国药理学通报,2016,(08):1158.[doi:10.3969/j.issn.1001-1978.2016.08.025]
 GUO Min,ZHANG Xian-wu,MA Tian-yu,et al.Effect of Aβ25-35 on Bcl-2, Bax gene promoter DNA methylation in SH-SY5Y cell[J].Chinese Pharmacological Bulletin,2016,(08):1158.[doi:10.3969/j.issn.1001-1978.2016.08.025]

备注/Memo

备注/Memo:
收稿日期:2018-04-18,修回日期:2018-05-25
基金项目:国家自然科学基金资助项目(No 81360049,81560694,81760015); 云南省科技厅-昆明医科大学联合专项重点项目(No 2014FA018); 云南省应用基础研究计划项目(No 2013FZ230,2013FZ231); 云南省中青年学术和技术带头人后备人选(No 2017HB053)
作者简介:张春芳(1990- ),女,硕士生,研究方向:肺动脉高压的基础,E-mail:zhangchunfangmd@163.com;
邢西迁(1980- ),男,硕士,副教授,硕士生导师,研究方向:肺动脉高压的基础与临床,通讯作者,E-mail:xingxiqianmd@yahoo.com;
杨 姣(1980- ),女,硕士,讲师,研究方向:肺动脉高压的基础与临床,通讯作者,E-mail:yangjiaokmu@yahoo.com
更新日期/Last Update: 2018-07-26